Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Core Insights - Vera Therapeutics is advancing its lead product candidate, atacicept, towards potential FDA approval and commercialization, with a priority review granted for its Biologics License Application (BLA) [2][6][7] - The company reported a significant increase in net loss for the year ended December 31, 2025, amounting to $299.6 million, compared to a net loss of $152.1 million in 2024 [5][17] - Vera Therapeutics has a strong financial position with $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which is expected to fund operations beyond the anticipated approval and U.S. commercial launch of atacicept [8][18] Business Highlights - In 2025, Vera Therapeutics achieved key milestones, including positive Phase 3 data from the ORIGIN study of atacicept in IgA nephropathy (IgAN) and the establishment of a leadership position in the IgAN space [2][6][10] - The ORIGIN Phase 3 trial met its primary endpoint with a statistically significant reduction in proteinuria, and the safety profile of atacicept was comparable to placebo [11][12] - The company appointed James R. Meyers to its Board of Directors, bringing over three decades of commercial leadership experience [7] Financial Results - For the year ended December 31, 2025, total operating expenses were $315.5 million, up from $167.2 million in 2024, with research and development expenses increasing to $215.3 million [17] - The net loss per diluted share increased to $4.66 in 2025 from $2.75 in 2024 [5][17] - Cash used in operating activities rose to $241.1 million in 2025, compared to $134.7 million in 2024 [8] Upcoming Milestones - The FDA has set a PDUFA date of July 7, 2026, for the atacicept BLA, with a potential commercial launch expected in mid-2026 [6][7] - Initial results from the PIONEER Phase 2 trial, evaluating atacicept in expanded IgAN populations and other autoimmune kidney diseases, are anticipated in the first half of 2026 [7] - Completion of the ORIGIN 3 study with two-year eGFR data is expected in 2027 [7]